Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.) [Internet]

Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.) [Internet]

Review

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.

PMID: 31305971
Bookshelf ID: NBK544012

Excerpt

The objective of this review was to perform a systematic review of the beneficial and harmful effects of semaglutide (SEM) at the recommended dose for the treatment of adult patients with Type 2 diabetes mellitus.

Sections

Abbreviations
Executive Summary
Introduction
Objectives and Methods
Results
Discussion
Conclusions
Appendix 1. Patient Input Summary
Appendix 2. Literature Search Strategy
Appendix 3. Excluded Studies
Appendix 4. Detailed Outcome Data
Appendix 5. Summary of Indirect Comparisons of Second-Line Therapy
Appendix 6. Summary of Indirect Comparisons of Second- or Third-Line Therapy
Appendix 7. Summary of Indirect Comparison Evaluating Mortality
References

Publication types

Review

Grants and funding

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.